The state of COPD in Belgium


- 561,000 people are affected by COPD,^{1*} and prevalence is rising.²
- COPD is the sixth leading cause of death.^{1*}
- Direct costs are over €1,900 per person, driven by late diagnosis and hospital readmissions.^{3†}
- Annual economic loss due to COPD is estimated to be more than €14 billion.^{4§}

 * 2021 data $^{+}$ 2019 data $^{\$}$ 2017 data

COPD is a highly debilitating and often fatal lung disease⁵

Chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis, deteriorates people's lung function – restricting their airflow, making it increasingly difficult to breathe and potentially affecting every facet of a person's life.⁵ The severity of the disease increases as it progresses and people with COPD can experience flare-ups that, when severe, require emergency hospital admission.⁵ However, appropriate care can improve lung health and quality of life for people with COPD.⁵


Challenges



Spirometry is not regularly performed in primary care to detect and diagnose COPD, despite being a globally-recommended diagnostic test that is reimbursed in primary care.⁵⁶ This may be due to time constraints and a shortage of professionals trained to perform assessments.⁶



Limited awareness of COPD creates a barrier to diagnosis, treatment and social care support services, such as disabled parking permits.⁶⁷



Reimbursement policies for pulmonary rehabilitation are

complex, creating uncertainty about coverage, referral pathways and whether financial circumstances may be a barrier to accessing this globally recommended intervention which promotes physical activity and mental wellbeing for people with respiratory disease.⁵⁶

REGENERON

'There have been so many initiatives around some diseases, such as cancer for raising funds, or developing healthcare pathways such as for diabetes or chronic kidney disease. But this is not the case for COPD.'

- Prof. Dr Eric Marchand, Department of Pneumology, CHU UCL Namur, Godinne and Belgian Respiratory Society COPD Work Group

Roche

sanofi

Living with COPD: Victor's story/

Victor was listening to the radio on World COPD Day in 2005 and heard a doctor describing symptoms of the disease. The doctor's warning about its association with tobacco use inspired Victor to quit smoking immediately. However, when Victor presented to his doctor with those very symptoms, he was told they were a normal manifestation of quitting. Three months later, another medical appointment also failed to correctly diagnose his condition. Finally, after a further three months without improvement, Victor sought out the doctor he had heard on the radio and was immediately diagnosed with COPD.



Speak Up for COPD is supported by a coalition of partners across the non-profit sector and pharmaceutical industry to establish COPD as a public health priority. Funding is provided by pharmaceutical industry partners. All partners contributed to this document.

GLOBAL ALLERGY & AIRWAYS



How is COPD being prioritised?

National policies

Overall status: moderate

In 2022, a resolution was passed calling for the federal government to develop an effective and comprehensive approach to COPD covering all of Belgium,⁸ but it does not yet exist.

Clinical guidance

Overall status: poor

In the absence of national clinical guidelines, most pulmonologists refer to the Global Strategy for Prevention, Diagnosis and Management of COPD (GOLD) recommendations.9 However, its use is inconsistent.6

Data collection

Overall status: moderate

There is no federal registry on COPD, but data collection surveys exist.¹⁰

Case studies

Pharmacists in Belgium are encouraged to support people living with COPD and other chronic lung diseases.¹¹ During oneto-one conversations. pharmacists can deliver information, provide coaching on inhaler technique and therapy adherence, and offer advice on ways to prevent flareups, such as seasonal flu vaccinations and smoking cessation programmes.

Policymakers must take action to:



ensure proper and timely use of spirometry to detect COPD by training and certifying dedicated respiratory nurses to support diagnosis, care and long-term management; and incorporating spirometry training in other medical curricula



expand the use of pharmacists to support people living with chronic respiratory diseases, including in prevention, screening, management and treatment optimisation of COPD



provide clear and comprehensive reimbursement for the delivery of multidisciplinary, guideline-recommended, best-practice COPD care, including pulmonary rehabilitation.

Contributors

We are grateful to the following individuals, whose valuable insights shaped the development of this country profile: Victor Nevelsteen, Flemish COPD Patient Association

Prof. Dr Eric Marchand, Department of Pneumology, CHU UCL Namur, Godinne; Belgian Respiratory Society COPD Work Group

Dr Rudi Peché, CHU Charleroi

Gitta Vanpeborgh, former Member of the Chamber of Representatives of Belgium

References

- Global Burden of Disease Collaborative Network. 2024. Global Burden of Disease Study 2021 (GBD 2021). Institute for Health Metrics and Evaluation (IHME)
- Benjafield A, Tellez D, Barrett M, et al. 2021. Eur Respir J 58(suppl 65): OA2866
- Rehman AU, Hassali MAA, Muhammad SA, et al. 2020. Eur J Health Econ 21(2): 181-94 Chen S, Kuhn M, Prettner K, et al. 2023. Lancet Glob Health 11(8): e1183-e93 3
- Global Initiative for Chronic Obstructive Lung Disease. 2024. Global strategy for the diagnosis, 5
- management, and prevention of chronic obstructive pulmonary disease. GOLD Leemans G, Vissers D, Ides K, et al. 2023. Int J Chron Obstruct Pulmon Dis 18: 2105-15
- 6.
- 7 Nevelsteen V. 2024. Personal communication by email: 08/05/24
- Résolution relative à une approche efficace et intégrale de lutte contre la broncho-pneumopathie 8. chronique obstructive. DOC 55 2259/007. 2022. Belgium: 2022 a
- Decramer M, Brusselle G, Buffels J, et al. 2013. Acta Clin Belg 68(5): 325-40
 Sciensano. 2022. Belgian National Burden of Disease Study.

© The Health Policy Partnership, 2024. All rights reserved. Date of preparation: August 2024. Veeva ID: Z4-66515 Please cite this document as: Whicher CH, Wait S, Habashi L. 2024. The state of COPD in Belgium. London: The Health Policy Partnership

^{11.} International Pharmaceutical Federation. 2022. Chronic respiratory diseases: a handbook for pharmacists. FIP